Literature DB >> 21789093

Hormone therapy in the management of prostate cancer: evidence-based approaches.

Leonard G Gomella1, Jaspreet Singh, Costas Lallas, Edouard J Trabulsi.   

Abstract

Hormonal therapy has been the standard for advanced prostate cancer for over 60 years. Recently, the utility of androgen ablation through various means has been demonstrated for earlier stages of disease. In particular, the strongest evidence to date involves the use of hormonal therapy in combination with radiation therapy. In this article we review the basic concepts in hormonal ablation for prostate cancer and review the evidence-based studies that support the use of hormonal therapy in early stage prostate cancer.

Entities:  

Keywords:  androgen deprivation therapy; combined androgen blockade; hormonal therapy; prostate cancer

Year:  2010        PMID： 21789093      PMCID： PMC3126080          DOI： 10.1177/1756287210375270

Source DB:  PubMed          Journal:  Ther Adv Urol        ISSN： 1756-2872


  49 in total

1.  Supraadditive apoptotic response of R3327-G rat prostate tumors to androgen ablation and radiation.

Authors:  D L Joon; M Hasegawa; C Sikes; V S Khoo; N H Terry; G K Zagars; M L Meistrich; A Pollack
Journal:  Int J Radiat Oncol Biol Phys       Date:  1997-07-15       Impact factor: 7.038

Review 2.  Global update on the use of hormonal therapy for the management of high-risk prostate cancer: introduction.

Authors:  Leonard G Gomella
Journal:  BJU Int       Date:  2007-01       Impact factor: 5.588

3.  Guideline for the management of clinically localized prostate cancer: 2007 update.

Authors:  Ian Thompson; James Brantley Thrasher; Gunnar Aus; Arthur L Burnett; Edith D Canby-Hagino; Michael S Cookson; Anthony V D'Amico; Roger R Dmochowski; David T Eton; Jeffrey D Forman; S Larry Goldenberg; Javier Hernandez; Celestia S Higano; Stephen R Kraus; Judd W Moul; Catherine M Tangen
Journal:  J Urol       Date:  2007-06       Impact factor: 7.450

Review 4.  Androgen deprivation therapy and estrogen deficiency induced adverse effects in the treatment of prostate cancer.

Authors:  S J Freedland; J Eastham; N Shore
Journal:  Prostate Cancer Prostatic Dis       Date:  2009-09-01       Impact factor: 5.554

5.  Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate.

Authors:  C Huggins; C V Hodges
Journal:  CA Cancer J Clin       Date:  1972 Jul-Aug       Impact factor: 508.702

6.  Neoadjuvant hormonal therapy prior to radical prostatectomy: the European experience.

Authors:  F M Debruyne; W P Witjes
Journal:  Mol Urol       Date:  2000

Review 7.  Optimizing hormone therapy in localized prostate cancer: focus on external beam radiotherapy.

Authors:  Howard M Sandler
Journal:  J Urol       Date:  2004-11       Impact factor: 7.450

8.  Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial.

Authors:  Michel Bolla; Laurence Collette; Léo Blank; Padraig Warde; Jean Bernard Dubois; René-Olivier Mirimanoff; Guy Storme; Jacques Bernier; Abraham Kuten; Cora Sternberg; Johan Mattelaer; José Lopez Torecilla; J Rafael Pfeffer; Carmel Lino Cutajar; Alfredo Zurlo; Marianne Pierart
Journal:  Lancet       Date:  2002-07-13       Impact factor: 79.321

9.  Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial.

Authors:  Anders Widmark; Olbjørn Klepp; Arne Solberg; Jan-Erik Damber; Anders Angelsen; Per Fransson; Jo-Asmund Lund; Ilker Tasdemir; Morten Hoyer; Fredrik Wiklund; Sophie D Fosså
Journal:  Lancet       Date:  2008-12-16       Impact factor: 79.321

10.  Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group.

Authors:  Fernando E C Calais da Silva; Aldo V Bono; Peter Whelan; Maurizio Brausi; Anton Marques Queimadelos; Jose A Portillo Martin; Ziya Kirkali; Fernando M V Calais da Silva; Chris Robertson
Journal:  Eur Urol       Date:  2009-02-21       Impact factor: 20.096
View more
  11 in total

1.  Findings from the Initial Use of the Healthy Homes Rating System (HHRS) in Three American Cities.

Authors:  Katelyn Burkart; Jonatan Martinez; Alicia Streater; Lyke Thompson
Journal:  J Urban Health       Date:  2017-06       Impact factor: 3.671

2.  Testicular vs adrenal sources of hydroxy-androgens in prostate cancer.

Authors:  Tianzhu Zang; Mary-Ellen Taplin; Daniel Tamae; Wanling Xie; Clementina Mesaros; Zhenwei Zhang; Glenn Bubley; Bruce Montgomery; Steven P Balk; Elahe A Mostaghel; Ian A Blair; Trevor M Penning
Journal:  Endocr Relat Cancer       Date:  2017-06-29       Impact factor: 5.678

3.  Is the detection rate of 18F-choline PET/CT influenced by androgen-deprivation therapy?

Authors:  Sotirios Chondrogiannis; Maria Cristina Marzola; Alice Ferretti; Gaia Grassetto; Anna Margherita Maffione; Lucia Rampin; Stefano Fanti; Francesco Giammarile; Domenico Rubello
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-02-25       Impact factor: 9.236

4.  From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer.

Authors:  Anna V Lapuk; Chunxiao Wu; Alexander W Wyatt; Andrew McPherson; Brian J McConeghy; Sonal Brahmbhatt; Fan Mo; Amina Zoubeidi; Shawn Anderson; Robert H Bell; Anne Haegert; Robert Shukin; Yuzhuo Wang; Ladan Fazli; Antonio Hurtado-Coll; Edward C Jones; Faraz Hach; Fereydoun Hormozdiari; Iman Hajirasouliha; Paul C Boutros; Robert G Bristow; Yongjun Zhao; Marco A Marra; Andrea Fanjul; Christopher A Maher; Arul M Chinnaiyan; Mark A Rubin; Himisha Beltran; S Cenk Sahinalp; Martin E Gleave; Stanislav V Volik; Colin C Collins
Journal:  J Pathol       Date:  2012-07       Impact factor: 7.996

Review 5.  TLX, an Orphan Nuclear Receptor With Emerging Roles in Physiology and Disease.

Authors:  Adam T Nelson; Yu Wang; Erik R Nelson
Journal:  Endocrinology       Date:  2021-11-01       Impact factor: 5.051

6.  LHRH Agonists for the Treatment of Prostate Cancer: 2012.

Authors:  Herbert Lepor; Neal D Shore
Journal:  Rev Urol       Date:  2012

7.  Adjuvant hormone therapy after radical prostatectomy in high-risk localized and locally advanced prostate cancer: First multicenter, observational study in China.

Authors:  Dingwei Ye; Wei Zhang; Lulin Ma; Chuanjun Du; Liping Xie; Yiran Huang; Qiang Wei; Zhangqun Ye; Yanqun Na
Journal:  Chin J Cancer Res       Date:  2019-06       Impact factor: 5.087

8.  Management of high-risk localized prostate cancer.

Authors:  Ariel E Marciscano; Matthew E Hardee; Nicholas Sanfilippo
Journal:  Adv Urol       Date:  2011-11-01

9.  What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 4: Experimental Treatments in Pre-Clinical Studies (Cell Lines and Mouse Models).

Authors:  Andrea Palicelli; Stefania Croci; Alessandra Bisagni; Eleonora Zanetti; Dario De Biase; Beatrice Melli; Francesca Sanguedolce; Moira Ragazzi; Magda Zanelli; Alcides Chaux; Sofia Cañete-Portillo; Maria Paola Bonasoni; Alessandra Soriano; Stefano Ascani; Maurizio Zizzo; Carolina Castro Ruiz; Antonio De Leo; Guido Giordano; Matteo Landriscina; Giuseppe Carrieri; Luigi Cormio; Daniel M Berney; Jatin Gandhi; Giacomo Santandrea; Martina Bonacini
Journal:  Int J Mol Sci       Date:  2021-11-14       Impact factor: 5.923

10.  miR-30e* is overexpressed in prostate cancer and promotes NF-κB-mediated proliferation and tumor growth.

Authors:  Shawn M Egan; Ellen Karasik; Leigh Ellis; Sandra O Gollnick
Journal:  Oncotarget       Date:  2017-06-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.